Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 4;11(1):242.
doi: 10.3390/jcm11010242.

Discordant Predictions of Extraglandular Involvement in Primary Sjögren's Syndrome According to the Anti-SSA/Ro60 Antibodies Detection Assay in a Cohort Study

Geoffrey Urbanski  1   2 , Aline Gury  1 , Pascale Jeannin  3   4 , Alain Chevailler  3 , Pierre Lozac'h  1   5 , Pascal Reynier  2 , Christian Lavigne  1 , Carole Lacout  1 , Emeline Vinatier  3   4
Affiliations

Discordant Predictions of Extraglandular Involvement in Primary Sjögren's Syndrome According to the Anti-SSA/Ro60 Antibodies Detection Assay in a Cohort Study

Geoffrey Urbanski et al. J Clin Med. .

Abstract

Electrophoresis-derived techniques for anti-SSA/Ro60 KDa (anti-SSA) antibodies detection have been progressively replaced by methods using non-native antigens. We aimed to compare the patients' phenotypes and the occurrence of extraglandular manifestations in primary Sjögren's syndrome according to the method used to detect anti-SSA antibodies. Sera from patients with a diagnosis of pSS according to ACR/EULAR 2016 criteria between 2008 and 2017 were tested for anti-SSA antibodies using methods with non-native antigens (magnetic bead multiplex assay; line immunoassays) and one with native antigens (counterimmunoelectrophoresis (CIE)). The population was split into three groups according to anti-SSA antibodies status: absence (SSA-), presence in any method except for CIE (SSA+CIE-), and presence in CIE (SSA+CIE+). The patients in the SSA+CIE+ group (n = 70, 42.7%) were ten years younger and presented more immunological activity compared with both the SSA- (n = 80, 48.8%) and SSA+CIE- groups (n = 14, 8.5%). The SSA- and SSA+CIE- groups were poorly distinct. The presence of anti-SSA antibodies solely in CIE was significantly associated with the occurrence of extraglandular manifestations of pSS (HR = 4.45 (2.35-8.42)). Contrary to CIE, methods using non-native antigens to detect anti-SSA antibodies were unable to predict the occurrence of systemic expression of pSS.

Keywords: anti-SSA antibodies; detection methods; primary Sjögren’s syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Extraglandular manifestations occurring after diagnosis in the 3 groups. Notes: the SSA− group referred to the patients with no anti-SSA antibodies. The SSA+CIE− referred to the patients with anti-SSA antibodies in any techniques except for counterimmunoelectrophoresis. The SSA+CIE+ referred to the patients with anti-SSA antibodies in counterimmunoelectrophoresis. CIE: counterimmunoelectrophoresis. The p-value on the graph represents the results of the comparison between the three curves using the log-rank test.
See this image and copyright information in PMC

References

    1. Daniels T.E., Criswell L.A., Shiboski C., Shiboski S., Lanfranchi H., Dong Y., Schiødt M., Umehara H., Sugai S., Challacombe S., et al. An Early View of the International Sjögren’s Syndrome Registry. Arthritis Rheum. 2009;61:711–714. doi: 10.1002/art.24397. - DOI - PMC - PubMed
    1. Seror R., Gottenberg J.E., Devauchelle-Pensec V., Dubost J.J., Le Guern V., Hayem G., Fauchais A.-L., Goeb V., Hachulla E., Hatron P.Y., et al. European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index and European League Against Rheumatism Sjögren’s Syndrome Patient-Reported Index: A Complete Picture of Primary Sjögren’s Syndrome Patients: ESSDAI and ESSPRI for Evaluation of Primary SS. Arthritis Care Res. 2013;65:1358–1364. doi: 10.1002/acr.21991. - DOI - PubMed
    1. Baldini C., Pepe P., Quartuccio L., Priori R., Bartoloni E., Alunno A., Gattamelata A., Maset M., Modesti M., Tavoni A., et al. Primary Sjögren’s Syndrome as a Multi-Organ Disease: Impact of the Serological Profile on the Clinical Presentation of the Disease in a Large Cohort of Italian Patients. Rheumatology. 2014;53:839–844. doi: 10.1093/rheumatology/ket427. - DOI - PubMed
    1. Brito-Zerón P., Acar-Denizli N., Ng W.-F., Zeher M., Rasmussen A., Mandl T., Seror R., Li X., Baldini C., Gottenberg J.-E., et al. How Immunological Profile Drives Clinical Phenotype of Primary Sjögren’s Syndrome at Diagnosis: Analysis of 10,500 Patients (Sjögren Big Data Project) Clin. Exp. Rheumatol. 2018;36((Suppl. S112)):102–112. - PubMed
    1. Anderson J.R., Gray K.G., Beck J.S., Kinnear W.F. Precipitating Autoantibodies in Sjogren’s Disease. Lancet Lond. Engl. 1961;2:456–460. doi: 10.1016/S0140-6736(61)92430-8. - DOI - PubMed